Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Brain scans may sharpen diagnosis of cognitive disorders

NCT ID NCT06463093

Diagnosis Sponsor: Central Hospital, Nancy, France Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at whether a special brain scan called 18F-FDG PET can help doctors tell the difference between cognitive problems caused by psychiatric conditions versus neurodegenerative diseases like Alzheimer's. Researchers studied 20 adults with cognitive impairment who had already received this scan as part of their care. They compared the diagnosis before and after the scan to see if it changed.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
18F-FDG (a radioactive tracer used in PET scans)
What this could lead to
If successful, this could show that PET scans help doctors more accurately diagnose the cause of cognitive problems, leading to better patient care.
What could go wrong
This is a very small, completed study with only 20 participants, so results may not apply to everyone. It only looked at whether diagnosis changed, not long-term outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

20 people

The number who actually took part.

Started

Nov 2024

Finished

Jul 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients treated for psychiatric reasons with neurocognitive disorders in the clinic, having consulted or being hospitalized at the psychotherapeutic center of Nancy between 01/01/2021 to 01/01/2024 and having undergone a flurodeoxyglucose positron emission tomography marked with fluorine 18 carried out in the course of care

Ages

18 to 80 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adult patients with cognitive impairment * Positron emission tomography with flurodeoxyglucose labeled with fluorine 18 carried out in the course of care Exclusion Criteria: * Patients objecting to the collection of their data

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Neurocognitive disorders are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

cognitive disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Neurocognitive disorders

Contacts and locations

Locations

  • Nancy's hospital

    Vandœuvre-lès-Nancy, 54511, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.